Clinical Trials
23 trialsNCT02523014 2026-06-02
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07428616 2026-05-27
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Recruiting
NCT06955169 2026-05-22
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Suspended
NCT05425004 2026-05-14
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Phase 2 Recruiting
NCT06275919 2026-05-13
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2 Recruiting
NCT04374305 2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2 Recruiting
NCT06804655 2026-05-06
EViDENCE-BT
University of Zurich
Phase 2 Not yet recruiting
NCT04082520 2026-04-22
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT07533942 2026-04-16
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT04659811 2026-04-15
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
Phase 2 Active not recruiting
NCT05940493 2026-03-13
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2 Recruiting
NCT03971461 2026-03-11
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
Phase 2 Active not recruiting
NCT04298541 2026-02-27
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Phase 2 Not yet recruiting
NCT06132685 2026-02-10
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
Phase 2 Recruiting
NCT03279692 2026-01-29
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT06439420 2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2 Completed
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03220646 2025-07-09
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03173950 2025-06-29
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02847559 2025-06-27
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Northwestern University
Phase 2 Recruiting